ArticleFrontiers in endocrinology2024
Analysis of sarcopenic obesity prevalence and diagnostic agreement according to the 2022 ESPEN and EASO Consensus in hospitalized older adults with severe obesity.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prevalence and impact of sarcopenic obesity at hospital admission according to ESPEN-EASO approach on functional status of older adults: results of a retrospective and prospective observational study.European journal of clinical nutrition · 2026Article
- Immunometabolic Plasticity in Sarcopenic Obesity: Toward a New Paradigm for Precision Immunonutrition.Nutrients · 2026Review
- Comparative Performance of SARC-F, SARC-CalF, SARC-F + EBM, and Ishii Score for Detecting Sarcopenia in Hospitalised Geriatric Patients.Journal of clinical medicine · 2026Article
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.Current obesity reports · 2026Review
- Water Extract of Polygonati Rhizoma Ameliorates Obesity-Related Skeletal Muscle Atrophy in Mice and C2C12 Myotubes.Nutrients · 2026Article
- Sarcopenia, Obesity, and Sarcopenic Obesity in Relation to Functional Limitations in Older Adults.Journal of clinical medicine · 2026Article
- Sarcopenic obesity in older adults: a scoping review of prevalence, assessment tools, associated factors, and interventions.Frontiers in public health · 2026Article
- Beyond body mass index: phenotypic and circulating biomarkers for the identification and characterization of sarcopenic obesity.Frontiers in nutrition · 2026Review
- Sexual Dimorphism in the Development of Cardiometabolic Syndrome.Handbook of experimental pharmacology · 2026Review
- The Prevalence of and Factors Associated with Sarcopenic Obesity, Sarcopenia, and Obesity Among Korean Adults: Findings from the 2022-2023 Korea National Health and Nutrition Examination Survey.Medicina (Kaunas, Lithuania) · 2025Article
- Sarcopenic obesity and weight loss-induced muscle mass loss.Current opinion in clinical nutrition and metabolic care · 2025Review
- Sarcopenia, Muscle Mass and Protein Intake in Adults Older Than 65 Years After Earlier Bariatric Surgery.Journal of cachexia, sarcopenia and muscle · 2025Observational
- Identifying Key Predictors of Sarcopenic Obesity in Italian Severely Obese Older Adults: Deep Learning Approach.Journal of clinical medicine · 2025Article
- Sarcopenic obesity and history of falls in older Italian adults: associations according to different diagnostic combinations.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenic obesity (SO) is a clinical disorder characterized by increased adiposity and decreased muscle mass and function, commonly observed in older adults. However, most of the studies that investigated SO prevalence rates were not based on current standardized diagnostic methods. Thus, this study aims to estimate the prevalence rates of SO and their level of agreement using different instruments proposed by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) Consensus, in a sample of hospitalized older adults with severe obesity. Methods: A cross-sectional study with 90 older adults (≥ 60 years) with severe obesity (body mass index ≥ 35 kg/m/²) seeking an in-hospital multidisciplinary body weight reduction program. Skeletal muscle function was assessed using the five-repetition Sit-Stand test (5-SSt) and Handgrip Strength (HGS). Body composition was evaluated by high percentages of fat mass (FM), low appendicular lean mass (ALM/W), and skeletal muscle mass (SMM/W), adjusted to body weight. The stage of SO was assessed on the presence of at least one comorbidity and specific cut-offs were adopted for each step. All analyses were performed according to gender and age range. Results: The prevalence rates of SO in the total sample were 23.3%, 25.5%, 31.1%, and 40.0% considering altered values of 5-SSt+FM+ALM/W, HGS+FM+ALM/W, 5-SSt+FMSSM/W, and HGS+FM+SSM/W, respectively. Higher prevalence rates were observed among female and old elderly subgroups, regardless of the diagnostic combination. There were weak agreements between the muscle function tests (5-SSt Conclusion: The discrepancies observed between the prevalence rates and their levels of agreement reinforce the need for new studies in similar populations aiming for better standardization of SO assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.